Michael Schweizer, MD

Michael Schweizer, MD

Assistant Professor, Medicine, Oncology
University of Washington School of Medicine
Assistant Member
Clinical Research Division

Education:

M.D., Temple University School of Medicine, 2008.
B.S., University of Delaware, Chemical Engineering, 2004

Research Focus:

  • Translational prostate cancer research
  • Novel therapeutics/drug development

Clinical Expertise:

Genitourinary oncology (Prostate, bladder, and testicular cancers)

Current Studies

  • A Phase II neoadjuvant study of enzalutamide, abiraterone acetate, prednisone, dutasteride and degarelix in men with localized prostate cancer pre-prostatectomy
  • A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer.

Recent Publications

1. Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precision Oncology (April 2019).

2. Schweizer, M.T., Gulati, R., Beightol, M., Konnick, E.Q., Cheng, H.H., Klemfuss, N., De Sarkar, N., Yu, E.Y., Montgomery, R.B., Nelson, P.S. & Pritchard, C.C. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. The Prostate (2019).

3. Marshall, C.H., Sokolova, A.O., McNatty, A.L., Cheng, H.H., Eisenberger, M.A., Bryce, A.H., Schweizer, M.T. & Antonarakis, E.S. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. European urology (2019).

4. Schweizer, M.T., Wang, H., Bivalacqua, T.J., Partin, A.W., Lim, S.J., Chapman, C., Abdallah, R., Levy, O., Bhowmick, N.A., Karp, J.M., De Marzo, A., Isaacs, J.T., Brennen, W.N. & Denmeade, S.R. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem cells translational medicine (2019).

5. Schweizer, M.T., Haugk, K., McKiernan, J.S., Gulati, R., Cheng, H.H., Maes, J.L., Dumpit, R.F., Nelson, P.S., Montgomery, B., McCune, J.S., Plymate, S.R. & Yu, E.Y. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PloS one 13, e0198389 (2018).

6. Teply, B.A., Wang, H., Luber, B., Sullivan, R., Rifkind, I., Bruns, A., Spitz, A., DeCarli, M., Sinibaldi, V., Pratz, C.F., Lu, C., Silberstein, J.L., Luo, J., Schweizer, M.T., Drake, C.G., Carducci, M.A., Paller, C.J., Antonarakis, E.S., Eisenberger, M.A. & Denmeade, S.R. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. The Lancet. Oncology 19, 76-86 (2018).

7. Bluemn, E.G., Coleman, I.M., Lucas, J.M., Coleman, R.T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R.F., Kaipainen, A., Corella, A.N., Yang, Y.C., Nyquist, M.D., Mostaghel, E., Hsieh, A.C., Zhang, X., Corey, E., Brown, L.G., Nguyen, H.M., Pienta, K., Ittmann, M., Schweizer, M., True, L.D., Wise, D., Rennie, P.S., Vessella, R.L., Morrissey, C. & Nelson, P.S. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer cell 32, 474-489.e476 (2017).

8. Guedes, L.B., Antonarakis, E.S., Schweizer, M.T., Mirkheshti, N., Almutairi, F., Park, J.C., Glavaris, S., Hicks, J., Eisenberger, M.A., De Marzo, A.M., Epstein, J.I., Isaacs, W.B., Eshleman, J.R., Pritchard, C.C. & Lotan, T.L. MSH2 Loss in Primary Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 23, 6863-6874 (2017).

9. Schweizer, M.T., Wang, H., Luber, B., Nadal, R., Spitz, A., Rosen, D.M., Cao, H., Antonarakis, E.S., Eisenberger, M.A., Carducci, M.A., Paller, C. & Denmeade, S.R. Bipolar Androgen Therapy for Men With Androgen Ablation Naive Prostate Cancer: Results From the Phase II BATMAN Study. The Prostate 76, 1218-1226 (2016).

10. Schweizer, M.T., Antonarakis, E.S., Wang, H., Ajiboye, A.S., Spitz, A., Cao, H., Luo, J., Haffner, M.C., Yegnasubramanian, S., Carducci, M.A., Eisenberger, M.A., Isaacs, J.T. & Denmeade, S.R. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Science translational medicine 7, 269ra262 (2015).

11. Schweizer, M.T., Zhou, X.C., Wang, H., Bassi, S., Carducci, M.A., Eisenberger, M.A. & Antonarakis, E.S. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. European urology 66, 646-652 (2014).

12. Schweizer, M.T., Zhou, X.C., Wang, H., Yang, T., Shaukat, F., Partin, A.W., Eisenberger, M.A. & Antonarakis, E.S. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 24, 2881-2886 (2013).

Full list of publications on PubMed



Additional Links & Information

Related Labs & Projects

View all labs & projects >
Michael Schweizer MD

Contact Information

Phone
(206) 606-6252
Fax
(206) 606-2042
Email
Additional contact

Mail Stop: G6-075